CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

This study is testing a combination of two advanced cell therapies — CAR-T cells (genetically engineered immune cells that target cancer markers) and dendritic cells (immune cells trained to recognize specific cancer proteins) — in people with relapsed or treatment-resistant leukemia or a high-risk pre-leukemia condition (MDS). **You may be eligible if...** - You are between 18 and 80 years old with a diagnosis of AML (acute myeloid leukemia), ALL (acute lymphoblastic leukemia), or high-risk MDS (myelodysplastic syndrome) that has not responded to or has relapsed after standard treatments - Your tumor cells express certain surface markers targeted by the therapy - You are in reasonably good health with adequate heart, lung, liver, and kidney function **You may NOT be eligible if...** - You have severe heart, lung, or kidney problems - You have an active autoimmune disease or are on immunosuppressive medications - You have active cancer spreading to the brain - You are pregnant or breastfeeding - You have HIV, Hepatitis B, or Hepatitis C - You have a severe psychiatric condition Talk to your doctor to see if this trial is right for you.